XTL completes direct public offering

Autoimmune company XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL) raised $2.5 million through the sale of 1 million ADSs at $2.50 in a registered direct offering with institutional investors...